MMS

Call Directions Website

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

As regulatory expectations evolve, sponsors face a critical challenge: how do you protect patient privacy while preservi...
10/12/2026

As regulatory expectations evolve, sponsors face a critical challenge: how do you protect patient privacy while preserving the scientific value of clinical data?

In this blog, Brittany Wright, PhD, Clinical Trial Transparency Specialist, MMS, and Himanshu Kumar Singh, Senior Business Development Manager, TrialAssure, explore how AI-powered anonymization can support compliance, reduce manual effort, and help sponsors maintain the integrity and usefulness of their clinical data.

Read more: https://hubs.li/Q04zzjBs0

Safety Review Committees (SRCs) and Data Monitoring Committees (DMCs) are making increasingly complex decisions, yet man...
10/09/2026

Safety Review Committees (SRCs) and Data Monitoring Committees (DMCs) are making increasingly complex decisions, yet many review processes still rely on static reports that can limit insight and slow decision-making. In this webinar, MMS experts will explore how interactive safety visualizations can help reviewers investigate emerging signals in real time, access participant-level data, and make more informed safety decisions.

Register today to join an insightful discussion with Chris Schoonmaker, Chief Operating Officer, Kris Wenzel, Director, Data Science, and Andrew Mills, Strategic Principal Statistician: https://hubs.li/Q04z70lg0

AI is giving small and mid-sized biotechs access to capabilities that were once out of reach, but success won't come fro...
10/08/2026

AI is giving small and mid-sized biotechs access to capabilities that were once out of reach, but success won't come from technology alone. The organizations that gain a competitive edge will be the ones that use AI to make better development, clinical, statistical, and regulatory decisions. Learn why smarter decision-making, not just faster processes, will define the next generation of biotech success in our latest blog from Irving Dark, Member of MMS Board of Directors, and Aiden Flynn, Senior Vice President, Strategic Statistical Services.

Read the blog: https://hubs.li/Q04zqjDv0

Great science deserves clear, strategic communication. At MMS, our medical writers play a critical role in helping innov...
10/07/2026

Great science deserves clear, strategic communication. At MMS, our medical writers play a critical role in helping innovative therapies move through development and toward patients.

We're expanding our global Medical Writing team and are hiring for multiple remote positions across the US, UK, and Canada, including:
- Senior Manager, Regulatory & Medical Writing (US & UK)
- Principal Medical Writer (UK)
- Senior Medical Writer (US & Canada)
- Senior Nonclinical Writer (Canada)

If you're passionate about scientific excellence, strategic thinking, and partnering with sponsors on complex development programs, we'd love to hear from you.

Explore our open opportunities and help shape the future of clinical development with a team recognized for expertise, collaboration, and innovation: https://hubs.li/Q04z6Yq_0

Transparency expectations continue to evolve across global clinical development.The UK's Phase 1 registration deferral o...
10/07/2026

Transparency expectations continue to evolve across global clinical development.

The UK's Phase 1 registration deferral option may provide added flexibility for sponsors, but navigating the associated requirements requires careful planning and a clear understanding of what obligations remain in place.

In this blog, Sharon Morton, Principal Regulatory Strategist, examines what the changes mean in practice and how sponsors can balance transparency with operational and commercial considerations.

Read more: https://hubs.li/Q04zqh_00

We're looking forward to attending the Clinical Trials Strategic Summit West Coast (CTSS WC) on October 7-8.Bringing a t...
10/05/2026

We're looking forward to attending the Clinical Trials Strategic Summit West Coast (CTSS WC) on October 7-8.

Bringing a therapy from concept to approval requires balancing innovation, efficiency, and informed decision-making. Whether you're exploring novel trial designs, looking to streamline development, or seeking greater confidence at critical program milestones, we'd welcome the opportunity to connect and exchange insights.

If you're attending, be sure to meet with Stephanie Liu, Director of Business Development, and Tina Tran, Director of Business Development, to discuss how MMS helps sponsors navigate complexity across the development lifecycle.
Book a meeting with our team: https://hubs.li/Q04z6_gt0

FDA's new Expedited IND Pilot Program and evolving approach to NAMs signal an important shift toward more collaborative,...
09/30/2026

FDA's new Expedited IND Pilot Program and evolving approach to NAMs signal an important shift toward more collaborative, human-relevant, and efficient development. But success will depend on how sponsors use that flexibility.

In her latest article, Uma Sharma, CEO, discusses what these developments mean for sponsors and why an integrated, evidence-driven approach remains the best strategy for accelerating development while maintaining scientific rigor.

Read more: https://hubs.li/Q04yJGR30

Aiden Flynn, Senior Vice President, Strategic Statistical Services, and Sal Siam, Director, Business Development, are lo...
09/29/2026

Aiden Flynn, Senior Vice President, Strategic Statistical Services, and Sal Siam, Director, Business Development, are looking forward to the Clinical Trials Strategic Summit (CTSS) in London tomorrow.

If you're attending, connect with Aiden and Sal to discuss how MMS helps sponsors accelerate development through data-driven insights, strategic biometrics expertise, and flexible clinical development solutions.

Book a meeting: https://hubs.li/Q04ypFqg0

We're proud to share that MMS has been shortlisted for Best CRO – Specialist Provider at the 2026 Scrip Awards. This rec...
09/29/2026

We're proud to share that MMS has been shortlisted for Best CRO – Specialist Provider at the 2026 Scrip Awards. This recognition reflects 20 years of helping sponsors navigate complex development challenges through scientific rigor, regulatory expertise, biometrics excellence, and data-driven innovation. From accelerated pathways and global submissions to advanced biostatistics, analytics, and insights powered by Datacise® and KerusCloud®, we're committed to helping sponsors make better development decisions and bring therapies to patients faster.

Congratulations to our global team and thank you to our clients for their continued trust.

Click here to learn more: https://hubs.li/Q04yz1W50

As we reflect on our ongoing 20 year anniversary celebrations, we want to express our gratitude for the strength of our ...
09/28/2026

As we reflect on our ongoing 20 year anniversary celebrations, we want to express our gratitude for the strength of our leadership.

For two decades, MMS has been led with the same values that inspired its founding in 2006, scientific excellence, innovation, and a people-first culture.

MMS has grown from a one-person consultancy to a global team of more than 1,000 colleagues, all while remaining focused on helping sponsors bring therapies to patients faster and more effectively.

To learn more about CEO Uma Sharma's journey and the vision that shaped MMS into the company it is today, read: https://hubs.li/Q04yr6Qs0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category